Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The company's offerings further extend to various MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB) and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), in addition to prepared formulations of these MDXX substances. The enterprise maintains its primary corporate offices in Vancouver, Canada.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITD.